FINWIRES · TerminalLIVE
FINWIRES

バンク・オブ・アメリカ証券は、アップルは第2四半期の好調な業績を受け、継続的な成長に向けて万全の態勢を整えていると述べている。

By

-- バンク・オブ・アメリカ証券は金曜日のレポートで、アップル(AAPL)は、iPhoneの売上高が22%増加、中国での売上高が28%回復、粗利益率が49.3%と好調だった第2四半期決算を受け、2026年まで継続的な成長に向けて良好な位置にあると述べた。 同社は、メモリ価格の逆風と供給制約にもかかわらず、第3四半期の売上高成長率を14%~17%、粗利益率を47.5%~48.5%と見込んでいる。また、25億台を超えるデバイスのインストールベースは、サービス事業の「継続的な2桁成長」を支えると予想される、とレポートは指摘している。 同証券は、予想を上回る世界的なiPhone需要、堅調な利益率、2026年に予定されている人工知能搭載Siriの発売、今年後半に予定されている折りたたみ式iPhone、そして製品戦略の強化につながる可能性のある経営陣交代計画など、複数の追い風要因を挙げている。 証券会社は、アップルは価格戦略と製品構成によってコスト圧力を管理できる一方、バランスシートを背景にAIへの投資を拡大できると述べ、2026年度の売上高予想を4,687億ドル、1株当たり利益予想を8.61ドルに引き上げた。 バンク・オブ・アメリカ・セキュリティーズはアップル株の買い推奨を維持し、目標株価を325ドルから330ドルに引き上げた。 アップル株は金曜日の取引で4%以上上昇した。

Price: $282.88, Change: $+11.53, Percent Change: +4.25%

Related Articles

Australia

Novartis Gains Canada Nod for Fabhalta in Rare Kidney Disease

Novartis (NVS) said Health Canada has approved Fabhalta for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.C3G is a rare, long-term kidney disease caused by an overactive immune pathway. This leads to a buildup of protein in the kidneys, causing inflammation, damage and, over time, loss of kidney function.The approval was backed by Phase III data showing a statistically significant reduction in proteinuria at six months, with sustained benefits through one year.Fabhalta (iptacopan) is an oral drug that blocks a key part of the immune system (Factor B), helping reduce the harmful activity that drives C3G and protects the kidneys.Price: $146.84, Change: $-1.01, Percent Change: -0.68%

$NVS
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Commvault Systems Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target price to $106, from $101, on a forward P/E of 21x our FY 27 EPS estimate of $5.05, below its three-year average. We increase our FY 27 EPS projection to $5.05 from $4.80, and start our FY 28 EPS forecast at $5.90. CVLT reported solid Q4 results, above consensus views, with total revenue rising 13% Y/Y to $312M, fueled by subscription revenue growth of 20% to $208M and strong SaaS revenue contribution of $93M (+43% Y/Y). SaaS ARR rose 42% to $400M, while subscription ARR hit $989M, up 27% Y/Y, with net new ARR of $53M marking the strongest quarterly performance of FY26. Results reflect momentum in the business as CVLT benefits from data security challenges from AI use. We anticipate long-term tailwinds, but note greater macro and demand uncertainty in FY 27. We highlight impressive FCF generation (record $132M) and continued margin expansion expected in the new fiscal year.

$CVLT
Commodities

US Soybean Crush Rose in March, Stocks Tightened, USDA Says

The US Department of Agriculture on Friday reported that soybean crush for March rose above February and year-ago totals, but stocks dropped.In its monthly Oilseed Crushings, Production, Consumption and Stocks Report, the USDA pegged soybeans crushed for crude oil at 6.82 million metric tons, or 227 mb, in March 2026, compared with 6.43 million mt, or 214 mb, in February 2026, and 6.20 million mt, or 207 mb, in March 2025.The amount of crude oil produced from crushed soybeans was 2.64 billion pounds, up 6% from February 2026 and up 7% from March 2025.Production of soybean oil, once refined, totaled 2 billion pounds in March 2026, up 14% from February 2026 and 7% from March 2025.Iowa facilities crushed a total of 1.5 million mt, followed by facilities in the North and Eastern US, totaling 1.3 million mt.Soybean-based crude oil stocks, as of March 31, 2026, totaled 2 billion pounds, slightly below 2.1 billion in February.Corn oil crushed to produce crude oil totaled 139 million pounds in March, above 132.7 million pounds in February.